HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Levallorphan

HCID 5359371
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
152-02-3
Standard SMILES
C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
InChIKey
OZYUPQUCAUTOBP-QXAKKESOSA-N
Molecular formula
C19H25NO
Average molar mass
283.4 g/mol
Monoisotopic mass
283.19361442

Overview

Levallorphan is a morphinane alkaloid.

Names & identifiers

Preferred name
Levallorphan
IUPAC
(1R,9R,10R)-17-prop-2-enyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
English name
levallorphan
Molecular formula
C19H25NO
Molecular weight
283.41

Names & synonyms

levallorphanNaloxiphan152-02-3Levallorphane17-Allylmorphinan-3-olLevalorfanoLevallorphanumLevallofanoN-Allyl-3-hydroxymorphinanL-N-Allyl-3-hydroxymorphinanDTXSID9023205(-)-3-Hydroxy-N-allylmorphinan
Show more names
C07069MCL 113
Levo-3-hydroxy-N-allyl morphinanMorphinan-3-ol, 17-allyl-Ro-1-7700Morphinan, 17-allyl-3-hydroxy-353613BU4UDTXCID703205(1R,9R,10R)-17-prop-2-enyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol(1R,9R,10R)-17-(prop-2-en-1-yl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-ol

Database identifiers

CAS
152-02-3
PubChem CID
5359371
DTXSID
DTXSID9023205
ChEMBL
CHEMBL1254682
ChEBI
CHEBI:6431
UNII
353613BU4U
EC Number
205-799-1
Nikkaji
J5.863G

Properties

Computed structural propertiesFilling in

XLogP
3.5
Topological polar surface area
23.5 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
2
Heavy atoms
21
Formal charge
0
Complexity
408

Experimental & physicochemical properties

Drugs · 2 items

DEA NFLIS-Drug Category -> Narcotics

Pharmaceuticals -> Listed in ZINC15

LogP3.9
Color/FormCRYSTALS FROM DILUTE ETHANOL
Solubility · 3 items

WHITE OR PRACTICALLY WHITE CRYSTALLINE POWDER; 1 G SOL IN ABOUT 20 ML WATER; PRACTICALLY INSOL IN ETHER; INSOL IN CHLOROFORM; 1 G SOL IN ABOUT 60 ML ALCOHOL /TARTRATE/

SOL IN WATER; SPARINGLY SOL IN ETHANOL; INSOL IN CHLOROFORM & DIETHYL ETHER

2.52e-02 g/L

Human DrugsPharmaceuticals
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point · 3 items

180-182 °C

CRYSTALS FROM ETHANOL; SPECIFIC OPTICAL ROTATION: -39 DEG @ 16 °C/D; MP: 176-177 °C /TARTRATE/

181 °C

Optical RotationSPECIFIC OPTICAL ROTATION: -88.9 DEG @ 20 °C/D (METHANOL, 3%)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Interactions...LEVALLORPHAN...SHOULD BE USED WITH CARE SINCE THEY MAY FURTHER EMBARASS RESPIRATION THAT HAS BEEN DEPRESSED BY ALCOHOL, BARBITURATES, OR RELATED CNS DEPRESSANTS.
Human Toxicity Excerpts · 5 items

ADVERSE REACTIONS INCL DYSPHORIA, MIOSIS, LETHARGY, DIZZINESS, DROWSINESS, GASTRIC UPSET & SWEATING. PALLOR, NAUSEA & SENSE OF HEAVINESS IN LIMBS MAY OCCUR. IN HIGH DOSAGE...MAY CAUSE PSYCHOTOMIMETIC MANIFESTATIONS, SUCH AS WEIRD DREAMS, VISUAL HALLUCINATIONS, DISORIENTATION, & FEELINGS OF UNREALITY. /TARTRATE/

WHEN ADMIN IN ABSENCE OF NARCOTIC...EXHIBIT SOME AGONIST PROPERTIES SUCH AS ANALGESIA, RESP DEPRESSION...& SUBJECTIVE EFFECTS... DESCRIBED AS EUPHORIA, WHICH MAY BE SIMILAR TO THAT INDUCED BY MORPHINE...INTOXICATION SIMILAR TO THAT PRODUCED BY SEDATIVES...HALLUCINATIONS. /TARTRATE/

...MOST PT SHOW RELAXATION & DROWSINESS, SIGNIFICANT PERCENTAGE EXPERIENCE... ANXIETY...DIFFICULTY IN FOCUSING EYES, SWEATING, NAUSEA...FEELING OF BEING GROGGY OR DRUNK...BEING SLEEPY BUT UNABLE TO SLEEP. THESE DYSPHORIC & PSYCHOTOMIMETIC EFFECTS APPEAR MORE...AS DOSE IS INCR... /NALORPHINE/

SMALL DOSES...PRODUCE CERTAIN AUTONOMIC EFFECTS RESEMBLING...MORPHINE. ... LOWERING OF BODY TEMP, SLIGHT DECR IN HEART RATE...CONSTRICTION OF PUPILS. RESP MIN VOL & SENSITIVITY OF RESP CENTER TO CO2 ARE REDUCED... SOME ANTAGONISTS OF NALORPHINE TYPE...INDUCE DIURESIS BY INHIBITING RELEASE OF ADH. /NALORPHINE/

LEVALLORPHAN (LORFAN)...CONSTRICTS PUPILS WHEN GIVEN SYSTEMICALLY TO NORMAL PEOPLE, BUT IT CAUSES PUPILS TO DILATE IN THOSE WHO ARE DEPENDENT UPON OPIOID DRUGS. THIS IS BASIS FOR CLINICAL TEST FOR OPIOID DEPENDENCY.

Non-Human Toxicity Excerpts · 2 items

THE NOCICEPTIVE REACTIONS OF NAIVE MICE & RATS PUT ON A HOT PLATE WERE ENHANCED BY LEVALLORPHAN. ENHANCING EFFECTS OF LEVALLORPHAN INCR WITH INCR DOSE UP TO AN OPTIMUM & REGRESSED @ HIGHER DOSES.

LEVALLORPHAN RAISED GROWTH HORMONE LEVELS, & LOWERED PROLACTIN LEVELS. PARTIAL AGONISTS SUPPRESSED MORPHINE-INDUCED PROLACTIN RELEASE.

Safety data

Chemistry & industry

Pharmacology

Pharmacodynamics · 1 item

Levallorphan, an opioid antagonist similar to naloxone, is used to treat drug overdoses. Levallorphan differs from naloxone in that it also possesses some agonist properties. It is an analogue of levelorphanol that counteracts the actions of narcotic analgesics such as morphine. It is used especially in the treatment of respiratory depression due to narcotic overdoses. Levallorphan prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.

Mechanism of Action · 3 items

Levallorphan antagonizes opioid effects by competing for the same receptor sites. It binds to the opioid mu receptor and the nicotinic acetylcholine receptor alpha2/alpha3.

SEE NARCOTIC ANTAGONISTS. ...ANTAGONISTS COMPETE WITH MORPHINE-LIKE DRUGS FOR STEREOSPECIFIC OPIOID RECEPTOR SITES & APPARENTLY OCCUPY THESE SITES WITHOUT INITIATING ANY RESPONSE. /NARCOTIC ANTAGONISTS/

SEE NARCOTIC ANTAGONISTS. ...IN ADDITION TO MAJOR OPIOID RECEPTOR, THERE IS SIMILAR BUT DISTINCT RECEPTOR...AT WHICH ANTAGONISTS...PRODUCE THEIR AGONISTIC EFFECTS. ... WHEN PROLONGED ACTION @ OPIOID RECEPTORS CAUSES PHYSICAL DEPENDENCE, PHYSIOLOGICAL SYSTEMS...DEVELOP...LATENT HYPEREXCITABILITY. /NARCOTIC ANTAGONISTS/

Biological Half-Life1 hour
Metabolism/Metabolites · 2 items

Hepatic.

LEVALLORPHAN, MORPHINE ANTAGONIST...IN RAT...WAS FOUND TO BE METABOLIZED TO 6BETA-HYDROXY DERIV.

MeSH Pharmacological ClassificationAgents inhibiting the effect of narcotics on the central nervous system.
Absorption, Distribution and Excretion · 3 items

Rapidly absorbed.

...MUCH MORE EFFECTIVE AFTER PARENTERAL THAN ORAL ADMIN, PROBABLY BECAUSE OF RAPID BIOTRANSFORMATION IN LIVER... FOLLOWING PARENTERAL ADMIN...CONCN IN BRAIN ARE 3-4 TIMES HIGHER THAN AFTER COMPARABLE DOSES OF MORPHINE. BRAIN CONCN FALL RAPIDLY & ONLY TRACE AMT ARE FOUND AFTER 4 HR. /NALORPHINE/

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Refractive IndexINDICES OF REFRACTION: 1.545 (ALPHA), 1.595 (BETA), 1.653 (GAMMA) /TARTRATE/
Physical DescriptionSolid
Stability/Shelf LifeSENSITIVE TO LIGHT /TARTRATE/
Dissociation ConstantsPKA= 4.5

Physicochemical properties

Melting point
180 · 180-182°
alpha
20 · D20 -88.9° (c = 3 in methanol)
Boiling point
425.96 °C · 425.96°C (rough estimate)
Density
1.026 · 1.0260 (rough estimate)
refractive index
1.5 · 1.5000 (estimate)
pka
10.17 · 10.17±0.20(Predicted)
FDA UNII
353613 BU4U · 353613BU4U
Hazardous Substances Data
152 · 152-02-3(Hazardous Substances Data)
Hazardous Substances Data
152-02-3(Hazardous Substances Data)

IN PT WITH SEVERE RESP DEPRESSION ANTAGONISM OF OPIOID EFFECTS IS SEEN WITHIN 1 OR 2 MINUTES AFTER IV INJECTION OF 5-10 MG OF NALORPHINE & LASTS 1-4 HR. PT MAY NOT SHOW COMPLETE REVERSAL OF SEDATIVE EFFECTS. /NALORPHINE/

Cellular LocationsMembrane
Metabolite PathwaysLevallorphan Action Pathway

Uses & manufacturing

Uses · 3 items

IN TREATMENT OF NARCOTIC-INDUCED RESP DEPRESSION /TARTRATE/

MEDICATION

MEDICATION (VET)

Methods of ManufacturingPREPN FROM 3-HYDROXY-N-METHYLMORPHINAN: SCHNIDER, GRUSSNER, HELV CHIM ACTA 34, 2211 (1951). ALTERNATE ROUTE: HELLERBACH ET AL, IBID 39, 429 (1956).
Formulations/PreparationsLEVALLORPHAN TARTRATE, NF, & LEVALLORPHAN TARTRATE INJECTION, NF (LORFAN), ARE ALSO AVAILABLE, LATTER IN CONCN OF 1 MG/ML. /TARTRATE/
Use ClassificationPharmaceuticals

Additional notes

DefinitionChEBI: Levallorphan is a morphinane alkaloid.